Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Oragenics is a biopharmaceutical company focused on oral health products and novel antibiotics. Its primary assets include the SMaRT Replacement Therapy (a genetically modified bacteria for tooth decay prevention), ProBiora3 (a commercialized oral probiotic blend), and MU1140-S (a synthetic lantibiotic for healthcare-associated infections). The company operates with a 1-for-20 reverse stock split effective September 24, 2010.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Net Revenue | $1,308,910 | $641,285 |
| Cost of Sales | $911,793 | $221,198 |
| Gross Profit | $397,117 | $420,087 |
| Operating Expenses | $8,299,788 | $6,751,590 |
| Net Loss | $(7,805,165) | $(5,519,348) |
| Cash Used in Operating Activities | $(6,448,434) | $(5,799,481) |
| Cash and Cash Equivalents (End of Period) | $132,103 | $301,592 |
| Working Capital | $(127,518) | $2,564,147 |
| Accumulated Deficit | $(33,317,048) | $(25,511,883) |
Debt and Liquidity: As of December 31, 2010, the company held a revolving note payable to a shareholder (Koski Family Limited Partnership) of $2,000,000. The company reported a working capital deficit of $127,518. Auditors have expressed substantial doubt regarding the company's ability to continue as a going concern.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 104% year-over-year, driven primarily by increased sales of ProBiora3 products ($1.13M in 2010 vs. $367k in 2009), partially offset by a decrease in grant revenues.
- Expense Increases: Operating expenses rose 23% to $8.3M. Selling, General, and Administrative (SG&A) expenses increased 28% due to higher advertising/marketing costs ($1.2M increase) and personnel costs. Research and Development (R&D) expenses increased 10% due to clinical trial costs for SMaRT Replacement Therapy.
- Inventory Reserves: The company established a significant inventory reserve of $255,814 in December 2010 due to a change in packaging for ProBiora3 products (from blister packs to bottles), resulting in scrap expense.
- Abandoned Offering: The company incurred a $603,012 loss in 2010 associated with an abandoned public offering registration statement.
- Going Concern: The company transitioned from positive working capital in 2009 to a deficit in 2010, necessitating reliance on shareholder credit facilities.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Capital Needs: Management states that existing cash and the amended Credit Facility with the Koski Family Limited Partnership (KFLP) are sufficient to fund operations only through June 2011. Additional financing is required to continue operations and advance product development.
- Product Pipeline:
- SMaRT Replacement Therapy: A second Phase 1 clinical trial using an attenuated strain is underway, expected to conclude in the second half of 2011. A clinical hold remains on the non-attenuated strain.
- MU1140-S: Preclinical testing is expected to conclude in the second half of 2011, with an Investigational New Drug (IND) application targeted for mid-2012.
- ProBiora3: The company is evaluating the mass retail channel due to capital constraints, having reduced store presence from ~17,000 to ~11,000 stores in early 2011.
Key Risks and Contingencies:
- Liquidity Risk: Substantial doubt exists regarding the ability to continue as a going concern. Failure to raise capital could force a curtailment of operations.
- Regulatory Risk: SMaRT Replacement Therapy faces FDA clinical holds. ProBiora3 relies on self-affirmed GRAS status; reclassification as a drug or cosmetic could halt sales.
- License Obligations: The company must spend $1,000,000 annually on R&D and pay minimum royalties to the University of Florida Research Foundation (UFRF) to maintain licenses for SMaRT and MU1140. Failure to meet these obligations could result in license termination.
- Management Changes: The CEO and President resigned in February 2011. The CFO is serving as the interim principal executive officer.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.5M credit facility with KFLP and the timeline for the next capital raise to bridge the gap beyond June 2011.
- License Compliance: Confirm that the $1M annual R&D spend and royalty payments to UFRF are being met to prevent termination of core IP licenses.
- Inventory Valuation: Assess the impact of the $255k inventory reserve and the success of the new packaging strategy for ProBiora3 products.
- Regulatory Status: Monitor the status of the FDA clinical hold on the non-attenuated SMaRT strain and the results of the ongoing Phase 1 trial.
- Revenue Concentration: Evaluate the sustainability of ProBiora3 sales given the reduction in mass retail distribution and the reliance on a few large retailers.